Therapeutic-Dose LMWH Cuts Thromboembolism, Deaths in COVID-19
Reduction in venous thromboembolism, arterial thromboembolism, and deaths seen in high-risk patients in non-ICU, but not ICU, settings
Reduction in venous thromboembolism, arterial thromboembolism, and deaths seen in high-risk patients in non-ICU, but not ICU, settings
Incidence of myocarditis 5.8 cases per 1 million adults after the second dose; safety signal for increased myocarditis seen in young men
Review shows median age of 21 years, involvement of 5 organ systems, and presentation 4 weeks after COVID-19
Most of the last 100,000 Americans to die from the disease did so in a period where vaccines were widely available
No association seen between step intensity in middle age and later mortality
Exactly who qualifies as high risk because of health or work reasons is not yet clear
This happened despite vast gains in scientific knowledge during the past century
Incidence of ischemic stroke, appendicitis, or acute myocardial infarction not increased 1 to 21 days after mRNA COVID-19 vaccination
The randomized, double-blind, placebo-controlled, multicenter PROVENT trial included 5197 participants aged 18 years and older who would benefit from AZD7442.
Older adults with chronic conditions report reading notes helped them to remember their care plan, medications